Form 4: Vertex Pharma EVP Sells Shares Under 10b5-1 Plan

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, sold 2,329 shares of common stock for $481.79 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc. (VRTX), reported a transaction involving the company's common stock.
• On March 13, 2026, Dr. Bozic sold 2,329 shares of VRTX common stock.
• The shares were sold at a price of $481.79 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was established on November 20, 2025.
• Following the reported sale, Dr. Bozic directly beneficially owns 35,405 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling.

Negatives

• An insider, EVP and CMO Carmen Bozic, sold 2,329 shares of common stock, which can sometimes be viewed negatively by the market, although this sale was pre-planned.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even those pre-arranged under Rule 10b5-1 plans, are common for executives managing personal finances and diversifying portfolios. While not inherently negative, significant or unexpected insider selling can sometimes be interpreted by the market as a signal regarding future company performance or valuation, though this specific transaction appears routine given the 10b5-1 plan.

Stakeholder Impact

• Shareholders: May observe an insider sale, which could be interpreted differently depending on individual investment strategies, though the 10b5-1 plan suggests a pre-planned, non-discretionary sale.

Key Dates

Recommendation

The insider sale by EVP and CMO Carmen Bozic is a pre-scheduled transaction under a Rule 10b5-1 plan, indicating it is not based on new material non-public information. This type of routine sale for personal financial management or diversification does not typically warrant a change in investment thesis for Vertex Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on the company's fundamentals rather than this specific insider transaction.

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Stock Sale, Carmen Bozic, 10b5-1 Plan, Pharmaceuticals, Biotech